Covance Blog - Sharing Innovation in Drug Development
      • Covance & FDNA to Develop Novel Program to Accelerate and Improve The Accuracy of Rare Disease Patient Recruitment for Clinical Studies

        Posted by
        Published On Mar 25 2019, 10:14 AM

        FDNA, a digital health company at the forefront of artificial intelligence (AI), genomics and precision medicine, and Covance will work together to create a new, innovative approach to clinical study recruitment for rare diseases.

        image of the world

        This novel program will utilize de-identified phenotypic data and artificial intelligence (AI) to help identify rare disease patients faster, more accurately and efficiently, with the goal of accelerating drug development. 

        More than 350 million people around the world live with a rare disease. Through this effort, Covance and FDNA aim to advance precision medicine for rare diseases and bring orphan drugs to market sooner.